CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+7.78%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.71B
AUM Growth
+$1.71B
(-2.4%)
Cap. Flow
+$34.6M
Cap. Flow
% of AUM
2.02%
Top 10 Holdings %
Top 10 Hldgs %
65.15%
Holding
68
New
6
Increased
13
Reduced
6
Closed
18
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$32.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$26.2M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$26.2M |
| 4 |
Immunovant
IMVT
|
$25.9M |
| 5 |
Structure Therapeutics
GPCR
|
$24.2M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$41.4M |
| 2 |
Design Therapeutics
DSGN
|
$32.4M |
| 3 |
89bio
ETNB
|
$25.6M |
| 4 |
Axsome Therapeutics
AXSM
|
$24.4M |
| 5 |
Viridian Therapeutics
VRDN
|
$20.2M |
Sector Composition
| 1 | Healthcare | 98.77% |
